



Recipient Information

1. Recipient Name

FLORIDA STATE UNIVERSITY
874 TRADITIONS WAY

TALLAHASSEE, 32306

2. Congressional District of Recipient

02

3. Payment System Identifier (ID)

1596001138A1

4. Employer Identification Number (EIN)

596001138

5. Data Universal Numbering System (DUNS)

790877419

6. Recipient's Unique Entity Identifier

JF2BLNN4PJC3

7. Project Director or Principal Investigator

Lisa B Hightow-Weidman, MD (Contact)
Professor
lhightowweidman@fsu.edu
919-966-6714

8. Authorized Official

Lizzy McCawley

Federal Agency Information

9. Awarding Agency Contact Information

Mahasin Ingram

EUNICE KENNEDY SHRIVER NATIONAL
INSTITUTE OF CHILD HEALTH & HUMAN
DEVELOPMENT
ingrammk@mail.nih.gov
(201) 780-0309

10. Program Official Contact Information

Denise Russo
Deputy Branch Chief, Pama Branch
EUNICE KENNEDY SHRIVER NATIONAL
INSTITUTE OF CHILD HEALTH & HUMAN
DEVELOPMENT
drusso1@mail.nih.gov
301-435-6871

Federal Award Information

11. Award Number

1UM2HD111102-01

12. Unique Federal Award Identification Number (FAIN)

UM2HD111102

13. Statutory Authority

42 USC 241 31 USC 6305 42 CFR Part 52

14. Federal Award Project Title

Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Scientific
Leadership Center

15. Assistance Listing Number

93.865

16. Assistance Listing Program Title

Child Health and Human Development Extramural Research

17. Award Action Type

New Competing

18. Is the Award R&D?

Yes

Summary Federal Award Financial Information

19. Budget Period Start Date 01/25/2023 – End Date 11/30/2023

20. Total Amount of Federal Funds Obligated by this Action	\$11,162,061
20 a. Direct Cost Amount	\$8,786,078
20 b. Indirect Cost Amount	\$2,375,983

21. Authorized Carryover

22. Offset

23. Total Amount of Federal Funds Obligated this budget period	\$11,162,061
--	--------------

24. Total Approved Cost Sharing or Matching, where applicable	\$0
---	-----

25. Total Federal and Non-Federal Approved this Budget Period	\$11,162,061
---	--------------

26. Project Period Start Date 01/25/2023 – End Date 11/30/2029

27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$11,162,061
--	--------------

28. Authorized Treatment of Program Income

Additional Costs

29. Grants Management Officer - Signature

Teri A. Pailen

30. Remarks

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise



Cooperative Agreement
Department of Health and Human Services
National Institutes of Health

Notice of Award



EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

SECTION I – AWARD DATA – 1UM2HD111102-01

Principal Investigator(s):

Lisa B Hightow-Weidman (contact), MD
Sybil Hosek, PHD

Award e-mailed to: SRA-Pre@fsu.edu

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$11,162,061 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to FLORIDA STATE UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR Part 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number UM2HD111102. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Teri A. Pailen
Grants Management Officer
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

Salaries and Wages	\$737,725
Fringe Benefits	\$228,890
Personnel Costs (Subtotal)	\$966,615
Consultant Services	\$69,250
Materials & Supplies	\$54,107
Travel	\$91,425
Other	\$2,207,006
Subawards/Consortium/Contractual Costs	\$5,397,675

Federal Direct Costs	\$8,786,078
Federal F&A Costs	\$2,375,983
Approved Budget	\$11,162,061
Total Amount of Federal Funds Authorized (Federal Share)	\$11,162,061
TOTAL FEDERAL AWARD AMOUNT	\$11,162,061

AMOUNT OF THIS ACTION (FEDERAL SHARE) **\$11,162,061**

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$11,162,061	\$11,162,061
2	\$10,463,649	\$10,463,649
3	\$10,333,316	\$10,333,316
4	\$10,283,125	\$10,283,125
5	\$10,173,415	\$10,173,415
6	\$10,161,519	\$10,161,519
7	\$10,113,635	\$10,113,635

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier: 1596001138A1
Document Number: UHD111102A
PMS Account Type: P (Subaccount)
Fiscal Year: 2023

IC	CAN	2023	2024	2025	2026	2027	2028	2029
HD	8014710	\$11,162,061	\$10,463,649	\$10,333,316	\$10,283,125	\$10,173,415	\$10,161,519	\$10,113,635

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: MPIDB-DR / **OC:** 41026 / **Released:** Pailen, Teri 01/18/2023
Award Processed: 01/24/2023 12:08:43 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1UM2HD111102-01

SECTION III – STANDARD TERMS AND CONDITIONS – 1UM2HD111102-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of “Research and Development” at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This grant is excluded from Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) UM2HD111102. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of [Public Law 110-85](#)), the “responsible party” must register “applicable clinical trials” on the [ClinicalTrials.gov Protocol Registration System Information Website](#). NIH encourages registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/

This award provides support for one or more NIH defined Phase III Clinical Trials. The NIH Policy for research supported as an NIH Phase III Clinical Trial has been amended in Section II.B. of the NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research – Amended October 2001 (see http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm).

A description of plans to conduct analyses, as appropriate, by sex/gender and racial/ethnic groups must be included in clinical trial protocols. Cumulative subject accrual and progress in conducting subset analyses must be reported to NIH in the annual Progress Reports. Final analyses of sex/gender and racial/ethnic differences must be reported in the required Final Progress Report or Competitive Renewal Applications (or Contract Renewals/Extensions) as stated in Section II.B. of the Guidelines.

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution’s specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
- For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

SECTION IV – HD SPECIFIC AWARD CONDITIONS – 1UM2HD111102-01

Clinical Trial Indicator: Yes

This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

RESTRICTION: This award is being made without a currently valid certification of Institutional Review Board (IRB) approval and is issued with the following restriction: Only activities that are clearly severable and independent from activities that involve human subjects may be conducted pending NICHD acceptance of the certification of IRB review and approval. No funds may be drawn down from the Payment Management System and no obligations may be made against Federal funds for any research involving human subjects prior to issuance of a revised Notice of Award rescinding this restriction.

IRB approval verification must be submitted within 60 days of the date of this Notice of Award to the Grants Management Specialist (GMS). Please contact the GMS if the IRB approval will be delayed beyond 60 days. Failure to comply with the above requirements can result in suspension and/or termination of this award, withholding of support, audit disallowances, and/or other appropriate action.

This award includes funds for twelve months of support but is awarded for less than twelve months. Noncompeting Continuation awards will cycle on **December 01, 2023**. NICHD is taking this action to redistribute start dates more evenly throughout the fiscal year.

Due to the impact of the Coronavirus disease 2019 (COVID-19) outbreak, NICHD will consider providing greater flexibilities to recipients in meeting administrative, financial management and audit requirements. Please contact the Grants Management Specialist and Program Official indicated on this Notice of Award for more information.

In accordance with the NICHD FY2023 fiscal policy, escalation on recurring costs has been removed. See NICHD Funding Strategies for Fiscal Year 2023.

The recipient must follow the Multiple Principal Investigator Leadership Plan included in the application dated **11/05/2022** and may not implement any changes in the plan without written NICHD prior approval.

Although the signatures of all PI/PD(s) are not required on prior approval requests, the recipient institution must secure and retain the signatures of all of PI/PD(s) within their own internal processes. See NIH Guide Notice [NOT-OD-06-054](#).

Beginning January 2021, for all competing applications or new protocols, the NICHD expects investigators for ALL NICHD Clinical Trials to abide by the requirements stated in NIH Guide Notice [NOT-HD-20-036](#) "NICHD Data Safety Monitoring Guidelines for Extramural Clinical Trials and Clinical Research". All NICHD applications which include Clinical Trials must include a Data Safety Monitoring Plan. All NIH-sponsored multi-site clinical trials, NIH-defined Phase III clinical trials and some single site clinical trials that pose potential risk to participants require Data and Safety Monitoring Board (DSMB) oversight. Applicants are expected to establish an independent, external DSMB when required by this policy.

Beginning January 2021, for all competing applications or new protocols, the NICHD expects investigators for ALL human subject research to abide by the requirements stated in NIH Guide Notice [NOT-HD-20-035](#) "NICHD Serious Adverse Event, Unanticipated Problem, and Serious Adverse Event Reporting Guidance".

For all competing applications or new protocols, the NICHD expects investigators for ALL NICHD Clinical Trials to abide by the requirements stated in NIH Guide Notice [NOT-HD-20-036](#) "NICHD Data Safety Monitoring Guidelines for Extramural Clinical Trials and Clinical Research". All NICHD applications which include Clinical Trials must include a Data Safety Monitoring Plan. All NIH-sponsored multi-site clinical trials, NIH-defined Phase III clinical trials and some single site clinical trials that pose potential risk to participants require Data and Safety Monitoring Board (DSMB) oversight. Applicants are expected to establish an independent, external DSMB when required by this policy.

For all competing applications or new protocols, the NICHD expects investigators for ALL human subject research to abide by the requirements stated in NIH Guide Notice [NOT-HD-20-035](#) "NICHD Serious Adverse Event, Unanticipated Problem, and Serious Adverse Event Reporting Guidance".

SPREADSHEET SUMMARY

AWARD NUMBER: 1UM2HD111102-01

INSTITUTION: FLORIDA STATE UNIVERSITY

Budget	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6	Year 7
Salaries and Wages	\$737,725	\$770,540	\$751,040	\$767,707	\$754,951	\$1,013,454	\$974,867
Fringe Benefits	\$228,890	\$240,084	\$234,159	\$239,223	\$236,572	\$314,932	\$301,943
Personnel Costs (Subtotal)	\$966,615	\$1,010,624	\$985,199	\$1,006,930	\$991,523	\$1,328,386	\$1,276,810
Consultant Services	\$69,250	\$69,250	\$69,250	\$69,250	\$69,250	\$69,250	\$69,250
Materials & Supplies	\$54,107	\$50,465	\$44,168	\$53,132	\$39,191	\$126,235	\$161,476
Travel	\$91,425	\$53,000	\$56,400	\$56,400	\$56,400	\$101,400	\$113,500
Other	\$2,207,006	\$1,940,667	\$1,962,702	\$1,968,576	\$2,003,078	\$2,292,163	\$2,954,614
Subawards/Consortium/Contractual Costs	\$5,397,675	\$5,428,905	\$5,472,329	\$5,379,321	\$5,261,674	\$4,059,371	\$3,067,134
ADP/Computer Services		\$88,000	\$30,000	\$30,000	\$30,000	\$45,000	
TOTAL FEDERAL DC	\$8,786,078	\$8,640,911	\$8,620,048	\$8,563,609	\$8,451,116	\$8,021,805	\$7,642,784

TOTAL FEDERAL F&A	\$2,375,983	\$1,822,738	\$1,713,268	\$1,719,516	\$1,722,299	\$2,139,714	\$2,470,851
TOTAL COST	\$11,162,061	\$10,463,649	\$10,333,316	\$10,283,125	\$10,173,415	\$10,161,519	\$10,113,635

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6	Year 7
F&A Cost Rate 1	54%	54%	54%	54%	54%	54%	54%
F&A Cost Base 1	\$4,399,969	\$3,375,440	\$3,172,719	\$3,184,288	\$3,189,442	\$3,962,434	\$4,575,650
F&A Costs 1	\$2,375,983	\$1,822,738	\$1,713,268	\$1,719,516	\$1,722,299	\$2,139,714	\$2,470,851